BNS808

BNS808 is an orally active and selective cannabinoid-1 receptor (CB1R) antagonist (IC50 = 0.8 nM) with notable CB2R selectivity and minimal brain penetration. BNS808 is studied in research on obesity and its associated metabolic complications, such as metabolic dysfunctional-associated steatotic liver disease (MASLD) . BNS808 has reduced free drug availability for CNS entry, enhancing safety and minimizing drug-drug interactions through high plasma binding[1].

Product Specifications

CAS Number

[2836313-12-1]

UNSPSC

12352101

Target

Cannabinoid Receptor; Cytochrome P450

Related Pathways

GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Smiles

ClC1=CC=C(S(=O)(NC2CCCOC3=C(C4=CC=C(Cl)C=C4)N(C5=C(Cl)C=CC=C5)N=C23)=O)C=C1

Molecular Formula

C25H20Cl3N3O3S

Molecular Weight

548.87

References & Citations

[1]Gammal A, et al., Synthesis and Pharmacological Characterization of Novel Peripheral Cannabinoid-1 Receptor Blockers Based on a Tricyclic Scaffold. J Med Chem. 2025 Apr 21.